Date: October 8, 2025 PMID: PMC12505323 Category: N/A Authors: Shuqi Wang, Ying Yuan, Suyu Liu Abstract: The US Food and Drug Administration (FDA) launched Project Optimus to shift the objective of dose selection from the maximum tolerated dose to the optimal biological dose (OBD), optimizing the benefit-risk tradeoff. One approach recommended by the FDA's guidance is to conduct randomized trials comparing multiple doses. In this paper, using the selection design framewo

Date: August 31, 2025 PMID: PMC12409783 Category: N/A Authors: Yu Wang, Haichun Yang, Ruining Deng, Yuankai Huo, Qi Liu, Yu Shyr, Shilin Zhao Abstract: 40905789 Spatial transcriptomics (ST) integrates gene expression data with the spatial organization of cells and their associated histology, offering unprecedented insights into tissue biology. While existing methods incorporate either location-based or histology-informed information, none fully synergize gene expression, hist

Date: August 20, 2025 PMID: PMC12578602 Category: N/A Authors: John R Heard, Ian Pagano, Charles Rosser, Wei Shen Tan Abstract: 40846188 Objective: To evaluate the performance the Hematuria Cancer Risk Score (HCRS) in combination with the urine-based biomarker test Oncuria-Detect for the detection of bladder cancer in a cohort of patients referred for hematuria evaluation. Methods: A cohort of 365 patients undergoing microscopic and gross hematuria evaluation were prospective